Aromatase Inhibitors are drugs that prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy for postmenopausal women who have hormone-dependent breast cancer.
The American Society of Clinical Oncology (ASCO) is now recommending that physicians discuss use of the aromatase inhibitor exemestane (Aromasin) to prevent breast cancer in at-risk postmenopausal women.
A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen-receptor (ER)-positive breast cancer should receive a second estrogen-blocking medication after completing tamoxifen treatment.
Gabriel Hortobagyi, M.D., professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, will receive the Jane Cooke Wright Lectureship from the American Association for Cancer Research and its Minorities in Cancer Research membership group.
One-quarter of women who should take hormone-blocking therapies as part of their breast cancer treatment either do not start or do not complete the five-year course, according to a new study led by University of Michigan Comprehensive Cancer Center researchers.
For nearly a decade, breast cancer researchers studying the hormone therapy tamoxifen have been divided as to whether genetic differences in a liver enzyme affect the drug's effectiveness and the likelihood breast cancer will recur.
Results from the ATLAS study indicate that women with estrogen receptor-positive breast cancer should consider taking tamoxifen for up to 10 years after diagnosis.
Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.
ProStrakan Group plc announces today that it has acquired exclusive US commercial rights to Fareston (toremifene citrate) for the treatment of metastatic breast cancer in postmenopausal women.
Phase III trial results show that a combination of the aromatase inhibitor anastrozole and fulvestrant, an analog of estradiol that downgrades the estrogen receptor, is superior to anastrozole alone in prolonging progression-free survival in patients with metastatic breast cancer.
Results of a SWOG clinical trial published August 2 in the New England Journal of Medicine show the combination of anastrozole and fulvestrant extended the median survival time of women with hormone receptor-positive metastatic breast cancer by more than six months compared to women treated with a standard therapy of anastrozole alone (47.7 months vs 41.3 months).
Decoding the DNA of patients with advanced breast cancer has allowed scientists to identify distinct cancer "signatures" that could help predict which women are most likely to benefit from estrogen-lowering therapy, while sparing others from unnecessary treatment.
A new analysis may help doctors identify breast cancer patients who will benefit from treatment with the immune suppressant drug everolimus, say French researchers at the 4th IMPAKT Breast Cancer Conference in Brussels, Belgium.
Scientists at Washington University School of Medicine in St. Louis are using powerful DNA sequencing technology not only to identify mutations at the root of a patient's tumor - considered key to personalizing cancer treatment - but to map the genetic evolution of disease and monitor response to treatment.
Preoperative treatment with aromatase inhibitors increases the likelihood that postmenopausal women with estrogen receptor-positive breast cancer will be able to have breast-conserving surgery rather than a mastectomy, according to the results of a national clinical trial presented today at the Society of Surgical Oncology annual meeting in Orlando, Fla.
Aromatase inhibitors (AIs) prevent the conversion of androgens to estrogens, and could play a role in the development of breast cancer. This study of 36 pre-menopausal women consisted of a cross-over intervention trial to determine if there were differences between red wine and white wine in their effects on AIs.
Yet another study showed that more than a third of women taking a certain class of breast cancer drugs are so bothered by side effects that they stop taking the pills before their treatment is complete
last week at the San Antonio Breast Cancer Symposium, researchers announced encouraging results from studies of two cancer medications that appeared to keep breast cancer from advancing.
The addition of zoledronic acid to adjuvant endocrine therapy increased bone mineral density and reduced the risk for disease recurrence among postmenopausal women with early hormone receptor-positive breast cancer, according to new data from the ZO-FAST trial.
"I know I need this medicine to help lower my chance of cancer recurrence, but it makes my joints ache and stiff. It makes me feel old and I am not sure I can take this medication much longer."
A new study has found that an osteoporosis drug protects against the bone damaging side effects of certain breast cancer medications. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that some breast cancer patients could take zoledronic acid in addition to their anti-cancer medications to maintain bone health.